

# Neuroprotective Agents: Therapeutic Applications and Global Markets

<https://marketpublishers.com/r/N54F8628B60EN.html>

Date: June 2018

Pages: 133

Price: US\$ 1,250.00 (Single User License)

ID: N54F8628B60EN

## Abstracts

### Summary

According to the 2007 Global Burden of Disease report from the World Health Organization (WHO), more than 1 billion people worldwide suffered from neurological disorders, including stroke, Alzheimer's disease, epilepsy, Parkinson's disease (PD), brain injuries, and glaucoma and other eye disorders. Nearly 7 million people died from these diseases. According to the report, one in six people is stricken by a neurological disorder every year, many of them becoming seriously disabled.

In 2015, neurological disorders ranked as the leading cause of lifelong disabilities among the main disease groups and were the second most common cause of death. Stroke is the leading neurological disorder and it affects more than 15 million people every year worldwide, killing 5 million people and leaving an equal number of people with debilitating disabilities.

In 2015, AD affected more than 46 million people, and it was the second leading cause of death, after stroke. Neurodegenerative disorders such as AD, PD, multiple sclerosis (MS) and amyotrophic lateral sclerosis (ALS) ranked in the 10 most fatal incurable diseases.

As life spans increase, most of the neurological disorders are becoming more prevalent. Common diseases of advanced age such as glaucoma, AD-associated dementia, age-related macular degeneration (AMD), diabetic retinopathy and PD affect nearly one-fourth of adults over 60.

In the U.S., 1.5 million people suffer from a traumatic central nervous system (CNS)

injury each year. This number consists primarily of young adults and the elderly, due to reasons such as accidents, falls, sports- and work-related injuries, combat and self-harm. One-third of injury-related deaths in the U.S. are caused by traumatic brain injuries, which also lead to serious physical disabilities, cognitive disorders and neurodegenerative diseases.

Treating neurological disorders has proved to be greatly challenging. In addition to mostly insufficient clinical research in many neurological disorders, therapeutic limitations are due to a natural protective seal around the brain called the blood-brain barrier, which makes it extremely difficult to effectively diffuse a drug compound into the brain.

Neuroprotection is an approach to the treatment of neurological disorders through the use of therapies that are developed by learning from the brain's own tools to protect nerve cells from damage, degeneration and death. The human brain, by large and small biological molecules and certain types of cells, can promote growth, survival and differentiation to adapt to sudden changes, trauma and disease. Neuroprotective agents in global markets and clinical pipelines include small molecule drugs, therapeutic monoclonal antibodies, gene therapies, cell therapies and other agents.

The global market for neuroprotective agents was valued at \$REDACTED billion in 2016 and \$REDACTED billion. in 2017

## Contents

### **CHAPTER 1 INTRODUCTION**

Study Goals and Objectives  
Reasons for Doing This Study  
Scope of Report  
Information Sources  
Methodology  
Geographic Breakdown  
Analyst's Credentials  
Related BCC Research Reports

### **CHAPTER 2 SUMMARY AND HIGHLIGHTS**

### **CHAPTER 3 MARKET AND TECHNOLOGY BACKGROUND**

Neuroprotection  
Why Are Neuroprotective Therapies Needed?  
Neuroprotective Strategies  
Cerebrovascular Disease  
Stroke  
Neuroprotection in Stroke  
Neurodegenerative Disorders  
Parkinson's Disease  
Amyotrophic Lateral Sclerosis  
Multiple Sclerosis  
Alzheimer's Disease  
Huntington's Disease  
Spinal Muscular Atrophy  
Epilepsy  
Neuroprotection in Neurodegenerative Disorders  
Ophthalmic Diseases  
Glaucoma  
Nonarteritic Anterior Ischemic Optic Neuropathy  
Age-related Macular Degeneration  
Diabetic Retinopathy  
Neuroprotection in Ophthalmic Diseases  
Traumatic CNS Injuries

Traumatic Brain Injury  
Traumatic Spinal Cord Injuries  
Neuroprotection in Traumatic CNS Injuries

## **CHAPTER 4 MARKET BREAKDOWN BY TECHNOLOGY TYPE**

Therapeutic Agents  
Antisense Agents  
Anti-amyloid Agents  
Immune Response Modifiers  
Antioxidants  
Anti-angiogenic Agents  
Anti-Parkinson's Agents  
Anticonvulsants  
Ocular Hypotensives  
Thrombolytics  
Blood Thinning Agents  
Anti-dementia Agents  
Other Neuroprotective Agents  
Regenerative Medicine Products  
Brainstorm Cell Therapeutics' Nurown as First ALS Cell Therapy in the U.S.  
Neuronata-R to Expand to International ALS Markets  
Multistem Fast-tracked for Ischemic Stroke  
CEVA101 Advances in Traumatic Brain Injury Trials  
Asterias Biotherapeutics Snatches RMAT for Spinal Cord Injuries  
CTX0E03 Advances in PISCES II Trials for Stroke Disability

## **CHAPTER 5 MARKET BREAKDOWN BY THERAPEUTIC INDICATION**

Neuroprotective Agents for Cerebrovascular Disease  
Neuroprotective Agents for Neurodegenerative Disorders  
Neuroprotective Agents for Ophthalmic Diseases  
Neuroprotective Agents for Traumatic Central Nervous System Injuries

## **CHAPTER 6 MARKET BREAKDOWN BY REGION**

## **CHAPTER 7 COMPANY PROFILES**

AB SCIENCE S.A.

ACUCELA INC.  
AERIE PHARMACEUTICALS INC.  
ALLERGAN  
ASTRAZENECA PLC  
ATHERSYS INC.  
AVEXIS INC.  
BAYER HEALTHCARE  
BIOGEN INC.  
BRISTOL-MYERS SQUIBB CO.  
BOEHRINGER INGELHEIM  
BRAINSTORM CELL THERAPEUTICS INC.  
CELGENE CORP.  
CORESTEM INC.  
COVIS PHARMA  
DAIICHI SANKYO INC.  
EISAI INC.  
FORTRESS BIOTECH INC.  
GENERVON BIOPHARMACEUTICALS LLC  
GLAXOSMITHKLINE PLC  
GW PHARMACEUTICALS PLC  
H. LUNDBECK A/S  
JANSSEN PHARMACEUTICALS INC.  
MEDDAY PHARMACEUTICALS SAS  
MERCK SERONO S.A.  
MITSUBISHI PHARMA CORP.  
NEWRON PHARMACEUTICALS SPA  
NOVARTIS AG  
PFIZER INC.  
QUARK PHARMACEUTICALS INC.  
REGENERON PHARMACEUTICALS INC.  
RENEURON GROUP PLC  
ROCHE HOLDING AG  
SANOFI  
TEVA PHARMACEUTICAL INDUSTRIES LTD.  
UCB PHARMA S.A.  
VERTEX PHARMACEUTICALS INC.  
VTV THERAPEUTICS INC.  
ZOGENIX INC.

## List Of Tables

### LIST OF TABLES

- Summary Table: Global Market for Neuroprotective Agents, by Region, Through 2022
- Table 1: Global Market for Neuroprotective Agents, by Technology Type, Through 2022
- Table 2: Global Market for Neuroprotective Agents, by Application, Through 2022
- Table 3: Global Market for Therapeutic Agents, by Drug Class, Through 2022
- Table 4: Global Market for Antisense Agents, Through 2022
- Table 5: Global Market for Anti-Amyloid Agents, Through 2022
- Table 6: Neuroprotective Interferons Available in Global Markets, by Brand
- Table 7: Neuroprotective Monoclonal Antibodies Available in Global Markets, by Brand
- Table 8: Key Immune Response Modifiers in Clinical Development
- Table 9: Global Market for Immune Response Modifiers, Through 2022
- Table 10: Key Antioxidants in Clinical Development
- Table 11: Global Market for Antioxidants, Through 2022
- Table 12: Key Anti-angiogenic Agents in Clinical Development
- Table 13: Global Market for Anti-Angiogenic Agents, Through 2022
- Table 14: Global Market for Anti-Parkinson's Agents, Through 2022
- Table 15: Key Anticonvulsants in Clinical Development
- Table 16: Global Market for Anticonvulsants, Through 2022
- Table 17: Global Market for Ocular Hypotensives, Through 2022
- Table 18: Global Market for Thrombolytics, Through 2022
- Table 19: Global Market for Blood Thinning Agents, Through 2022
- Table 20: Global Market for Anti-Dementia Agents, Through 2022
- Table 21: Key Neuroprotective Drug Candidates with Novel MoA in Clinical Development
- Table 22: Global Market for Other Neuroprotective Agents, Through 2022
- Table 23: Global Market for Regenerative Medicine Products, Through 2022
- Table 24: Global Market Share for Key Players in Neuroprotection, 2017
- Table 25: Global Market for Neuroprotective Agents, by Therapeutic Indication, Through 2022
- Table 26: Global Market for Neuroprotective Agents Used in Treating Cerebrovascular Disease, Through 2022
- Table 27: Global Market for Neuroprotective Agents Used in Treating Neurodegenerative Disorders, by Type, Through 2022
- Table 28: Global Market for Neuroprotective Agents Used in Treating Ophthalmic Diseases, by Type, Through 2022
- Table 29: Global Market for Neuroprotective Agents Used in Treating Traumatic CNS

Injuries, by Type, Through 2022

Table 30: Global Market for Neuroprotective Agents, by Region, Through 2022

Table 31: North American Market for Neuroprotective Agents, by Indication, Through 2022

Table 32: European Market for Neuroprotective Agents, by Indication, Through 2022

Table 33: Asia-Pacific Market for Neuroprotective Agents, by Indication, Through 2022

Table 34: ROW Market for Neuroprotective Agents, by Indication, Through 2022

Table 35: Global Market for Neuroprotective Agents Used in Treating Cerebrovascular Disease, by Region, Through 2022

Table 36: Global Market for Neuroprotective Agents Used in Treating Neurodegenerative Disorders, by Region, Through 2022

Table 37: Global Market for Neuroprotective Agents Used in Treating Ophthalmic Diseases, by Region, Through 2022

Table 38: Global Market for Neuroprotective Agents Used in Treating Traumatic CNS Injuries, by Region, Through 2022

## List Of Figures

### LIST OF FIGURES

Summary Figure: Global Market for Neuroprotective Agents, by Region, 2016-2022

Figure 1: Global Market for Neuroprotective Agents, by Technology Type, 2016-2022

Figure 2: Global Market for Neuroprotective Agents, by Application, 2016-2022

Figure 3: Global Market for Therapeutic Agents, by Drug Class, 2016-2022

Figure 4: Global Market for Antisense Agents, 2016-2022

Figure 5: Global Market for Anti-Amyloid Agents, 2016-2022

Figure 6: Global Market for Immune Response Modifiers, 2016-2022

Figure 7: Global Market for Antioxidants, 2016-2022

Figure 8: Global Market for Anti-Angiogenic Agents, 2016-2022

Figure 9: Global Market for Anti-Parkinson's Agents, 2016-2022

Figure 10: Global Market for Anticonvulsants, 2016-2022

Figure 11: Global Market for Ocular Hypotensives, 2016-2022

Figure 12: Global Market for Thrombolytics, 2016-2022

Figure 13: Global Market for Blood Thinning Agents, 2016-2022

Figure 14: Global Market for Anti-Dementia Agents, 2016-2022

Figure 15: Global Market for Other Neuroprotective Agents, 2016-2022

Figure 16: Global Market for Regenerative Medicine Products, 2016-2022

Figure 17: Global Market Share for Key Players in Neuroprotection, 2017

Figure 18: Global Market for Neuroprotective Agents, by Therapeutic Indication, 2016-2022

Figure 19: Global Market for Neuroprotective Agents Used in Treating Cerebrovascular Disease, 2016-2022

Figure 20: Global Market for Neuroprotective Agents Used in Treating Neurodegenerative Disorders, by Type, 2017-2022

Figure 21: Global Market for Neuroprotective Agents Used in Treating Ophthalmic Diseases, by Type, 2016-2022

Figure 22: Global Market for Neuroprotective Agents Used in Treating Traumatic CNS Injuries, by Type, 2016-2022

Figure 23: Global Market for Neuroprotective Agents, by Region, 2016-2022

Figure 24: North American Market for Neuroprotective Agents, by Indication, 2016-2022

Figure 25: European Market for Neuroprotective Agents, by Indication, 2016-2022

Figure 26: Asia-Pacific Market for Neuroprotective Agents, by Indication, 2016-2022

Figure 27: ROW Market for Neuroprotective Agents, by Indication, 2016-2022

Figure 28: Global Market for Neuroprotective Agents Used in Treating Cerebrovascular Disease, by Region, 2016-2022



Figure 29: Global Market for Neuroprotective Agents Used in Treating Neurodegenerative Disorders, by Region, 2016-2022

Figure 30: Global Market for Neuroprotective Agents Used in Treating Ophthalmic Diseases, by Region, 2016-2022

Figure 31: Global Market for Neuroprotective Agents Used in Treating Traumatic CNS Injuries, by Region, 2016-2022

## I would like to order

Product name: Neuroprotective Agents: Therapeutic Applications and Global Markets

Product link: <https://marketpublishers.com/r/N54F8628B60EN.html>

Price: US\$ 1,250.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/N54F8628B60EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970